Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension

Travis Maestas, Lillian M. Hansen, Rebecca R. Vanderpool, Ankit Desai, Sophia Airhart, Shannon M. Knapp, Adam Cohen, Jeremy Feldman, Franz Rischard

Research output: Contribution to journalArticle

Abstract

Despite the increasing trends, reports on long-term follow-up are limited on transitioning from parenteral to oral treprostinil therapy in patients with pulmonary arterial hypertension (PAH). We investigated both the effectiveness of parenteral to oral treprostinil transition and the characteristics associated with transition failure over a duration of two years. The study included 37 Group I functional class I and II patients with PAH on combination therapy. Patients were excluded if cardiac index ≤2.2 L/min/m2, right atrial pressure ≥11 mmHg, or 6-min walk distance ≤250 m. Patients were categorized as successful (STransition) or unsuccessful (UTransition) transition based on clinical stability, or a parenteral comparator (CParenteral) if they remained on parenteral therapy (no transition). All patients underwent two right heart catheterizations, one at enrollment and a second post transition. Of 24 total transition patients, 46% were classified as UTransition. UTransition occurred on average 577 days post transition. Both UTransition and STransition had similar hemodynamics at diagnosis and treprostinil dose before and after transition. Before transition, the pulmonary vascular resistance (PVR) was significantly higher in the UTransition (6.7 ± 2 WU) vs. STransition group (3.5 ± 1.5 WU). At follow-up catheterization, the UTransition group demonstrated further increases in PVR, greater than the CParenteral group, without recovery despite “rescue” therapy in the UTransition group. A pre-transition PVR of 4.16 WU discriminated the UTransition from the STransition group. While a subset of PAH patients on combination therapy may be safely transitioned from parenteral to oral treprostinil, caution should be exercised in patients with elevated baseline PVR to avoid irreversible destabilization.

Original languageEnglish (US)
JournalPulmonary Circulation
Volume8
Issue number4
DOIs
StatePublished - Oct 1 2018

Fingerprint

Pulmonary Hypertension
Vascular Resistance
Therapeutics
Patient Transfer
Atrial Pressure
Cardiac Catheterization
treprostinil
Catheterization
Hemodynamics

Keywords

  • drug delivery
  • pulmonary arterial hypertension
  • right ventricle function and dysfunction

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension. / Maestas, Travis; Hansen, Lillian M.; Vanderpool, Rebecca R.; Desai, Ankit; Airhart, Sophia; Knapp, Shannon M.; Cohen, Adam; Feldman, Jeremy; Rischard, Franz.

In: Pulmonary Circulation, Vol. 8, No. 4, 01.10.2018.

Research output: Contribution to journalArticle

Maestas, Travis ; Hansen, Lillian M. ; Vanderpool, Rebecca R. ; Desai, Ankit ; Airhart, Sophia ; Knapp, Shannon M. ; Cohen, Adam ; Feldman, Jeremy ; Rischard, Franz. / Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension. In: Pulmonary Circulation. 2018 ; Vol. 8, No. 4.
@article{e2dd8c89811f4fef992a4fa4366deb33,
title = "Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension",
abstract = "Despite the increasing trends, reports on long-term follow-up are limited on transitioning from parenteral to oral treprostinil therapy in patients with pulmonary arterial hypertension (PAH). We investigated both the effectiveness of parenteral to oral treprostinil transition and the characteristics associated with transition failure over a duration of two years. The study included 37 Group I functional class I and II patients with PAH on combination therapy. Patients were excluded if cardiac index ≤2.2 L/min/m2, right atrial pressure ≥11 mmHg, or 6-min walk distance ≤250 m. Patients were categorized as successful (STransition) or unsuccessful (UTransition) transition based on clinical stability, or a parenteral comparator (CParenteral) if they remained on parenteral therapy (no transition). All patients underwent two right heart catheterizations, one at enrollment and a second post transition. Of 24 total transition patients, 46{\%} were classified as UTransition. UTransition occurred on average 577 days post transition. Both UTransition and STransition had similar hemodynamics at diagnosis and treprostinil dose before and after transition. Before transition, the pulmonary vascular resistance (PVR) was significantly higher in the UTransition (6.7 ± 2 WU) vs. STransition group (3.5 ± 1.5 WU). At follow-up catheterization, the UTransition group demonstrated further increases in PVR, greater than the CParenteral group, without recovery despite “rescue” therapy in the UTransition group. A pre-transition PVR of 4.16 WU discriminated the UTransition from the STransition group. While a subset of PAH patients on combination therapy may be safely transitioned from parenteral to oral treprostinil, caution should be exercised in patients with elevated baseline PVR to avoid irreversible destabilization.",
keywords = "drug delivery, pulmonary arterial hypertension, right ventricle function and dysfunction",
author = "Travis Maestas and Hansen, {Lillian M.} and Vanderpool, {Rebecca R.} and Ankit Desai and Sophia Airhart and Knapp, {Shannon M.} and Adam Cohen and Jeremy Feldman and Franz Rischard",
year = "2018",
month = "10",
day = "1",
doi = "10.1177/2045894018797270",
language = "English (US)",
volume = "8",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "4",

}

TY - JOUR

T1 - Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension

AU - Maestas, Travis

AU - Hansen, Lillian M.

AU - Vanderpool, Rebecca R.

AU - Desai, Ankit

AU - Airhart, Sophia

AU - Knapp, Shannon M.

AU - Cohen, Adam

AU - Feldman, Jeremy

AU - Rischard, Franz

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Despite the increasing trends, reports on long-term follow-up are limited on transitioning from parenteral to oral treprostinil therapy in patients with pulmonary arterial hypertension (PAH). We investigated both the effectiveness of parenteral to oral treprostinil transition and the characteristics associated with transition failure over a duration of two years. The study included 37 Group I functional class I and II patients with PAH on combination therapy. Patients were excluded if cardiac index ≤2.2 L/min/m2, right atrial pressure ≥11 mmHg, or 6-min walk distance ≤250 m. Patients were categorized as successful (STransition) or unsuccessful (UTransition) transition based on clinical stability, or a parenteral comparator (CParenteral) if they remained on parenteral therapy (no transition). All patients underwent two right heart catheterizations, one at enrollment and a second post transition. Of 24 total transition patients, 46% were classified as UTransition. UTransition occurred on average 577 days post transition. Both UTransition and STransition had similar hemodynamics at diagnosis and treprostinil dose before and after transition. Before transition, the pulmonary vascular resistance (PVR) was significantly higher in the UTransition (6.7 ± 2 WU) vs. STransition group (3.5 ± 1.5 WU). At follow-up catheterization, the UTransition group demonstrated further increases in PVR, greater than the CParenteral group, without recovery despite “rescue” therapy in the UTransition group. A pre-transition PVR of 4.16 WU discriminated the UTransition from the STransition group. While a subset of PAH patients on combination therapy may be safely transitioned from parenteral to oral treprostinil, caution should be exercised in patients with elevated baseline PVR to avoid irreversible destabilization.

AB - Despite the increasing trends, reports on long-term follow-up are limited on transitioning from parenteral to oral treprostinil therapy in patients with pulmonary arterial hypertension (PAH). We investigated both the effectiveness of parenteral to oral treprostinil transition and the characteristics associated with transition failure over a duration of two years. The study included 37 Group I functional class I and II patients with PAH on combination therapy. Patients were excluded if cardiac index ≤2.2 L/min/m2, right atrial pressure ≥11 mmHg, or 6-min walk distance ≤250 m. Patients were categorized as successful (STransition) or unsuccessful (UTransition) transition based on clinical stability, or a parenteral comparator (CParenteral) if they remained on parenteral therapy (no transition). All patients underwent two right heart catheterizations, one at enrollment and a second post transition. Of 24 total transition patients, 46% were classified as UTransition. UTransition occurred on average 577 days post transition. Both UTransition and STransition had similar hemodynamics at diagnosis and treprostinil dose before and after transition. Before transition, the pulmonary vascular resistance (PVR) was significantly higher in the UTransition (6.7 ± 2 WU) vs. STransition group (3.5 ± 1.5 WU). At follow-up catheterization, the UTransition group demonstrated further increases in PVR, greater than the CParenteral group, without recovery despite “rescue” therapy in the UTransition group. A pre-transition PVR of 4.16 WU discriminated the UTransition from the STransition group. While a subset of PAH patients on combination therapy may be safely transitioned from parenteral to oral treprostinil, caution should be exercised in patients with elevated baseline PVR to avoid irreversible destabilization.

KW - drug delivery

KW - pulmonary arterial hypertension

KW - right ventricle function and dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85054807008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054807008&partnerID=8YFLogxK

U2 - 10.1177/2045894018797270

DO - 10.1177/2045894018797270

M3 - Article

AN - SCOPUS:85054807008

VL - 8

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 4

ER -